Early and sustained non-HDL-c target achievement after MI -

Name: Early and sustained non-HDL-c target achievement after MI
Uploaded: 2024-11-04T05:00:00+00:00
Duration: 6 min 53 s
Description: ESC 2024 - Jessica Schubert shows that early and sustained non-HDL target achievement is associated with the lowest risk of MACE. "If the

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Cardiology
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Javier Morales, MD, FACP, FACE
- Javier Morales, MD, FACP, FACE
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Dr. Robert Giugliano
- Dr. Robert Giugliano
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Hyperlipidemia
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Erin Bohula, MD, DPhil
- Erin Bohula, MD, DPhil
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Hyperlipidemia
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Lawrence Leiter
- Lawrence Leiter

Early and sustained non-HDL-c target achievement after MI

Recommended

Title